Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 %
Aim. An efficacy assessment of steroid therapy in SARS-CoV-2 patients aged over 50 years with lung damage over 50 % (grade 3–4).Materials and methods. A retrospective study of 158 SARS-CoV-2 patients hospitalised in April—June 2020 was conducted under the inclusion criteria: age over 50 years, chest...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2021-10-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/600 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860107138564096 |
|---|---|
| author | O. Yu. Zolnikova R. V. Maslennikov V. T. Ivashkin N. L. Dzhakhaya O. Yu. Kiseleva N. D. Potskhverashvili S. A. Shorokhova |
| author_facet | O. Yu. Zolnikova R. V. Maslennikov V. T. Ivashkin N. L. Dzhakhaya O. Yu. Kiseleva N. D. Potskhverashvili S. A. Shorokhova |
| author_sort | O. Yu. Zolnikova |
| collection | DOAJ |
| description | Aim. An efficacy assessment of steroid therapy in SARS-CoV-2 patients aged over 50 years with lung damage over 50 % (grade 3–4).Materials and methods. A retrospective study of 158 SARS-CoV-2 patients hospitalised in April—June 2020 was conducted under the inclusion criteria: age over 50 years, chest computed tomography (CT) for COVID-19-asso-ciated pneumonia, C-reactive protein (CRP) >50 mg/L, anticoagulant therapy, no contraindications to steroids, no biologic therapy. Cohort 1 patients (n = 96) received dexamethasone 4–12 mg/day, cohort 2 (n = 62) — a standard non-dexamethasone therapy.Results. Dexamethasone treatment associated with a significant alleviation of COVID-19-associated pneumonia in CT score (p = 0.001), reduced fibrinogen (p = 0.001), a trend to CRP reduction by day 8–10 and lower demand for oxygen therapy, including ventilatory support (p = 0.001). Mortality rate was 19.8 and 75.8 % in cohorts 1 and 2, respectively (p = 0.001).Conclusion. Dexamethasone therapy 4–12 mg/day in SARS-CoV-2 patients aged 50+ years with grade 3–4 CT changes receiving LMWH from start of hospitalisation significantly improved CT scores and reduced mortality. |
| format | Article |
| id | doaj-art-185537965cb14b6dbf77061b4f8941c5 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2021-10-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-185537965cb14b6dbf77061b4f8941c52025-02-10T16:14:37ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732021-10-01313435010.22416/1382-4376-2021-31-3-43-50432Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 %O. Yu. Zolnikova0R. V. Maslennikov1V. T. Ivashkin2N. L. Dzhakhaya3O. Yu. Kiseleva4N. D. Potskhverashvili5S. A. Shorokhova6Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Aim. An efficacy assessment of steroid therapy in SARS-CoV-2 patients aged over 50 years with lung damage over 50 % (grade 3–4).Materials and methods. A retrospective study of 158 SARS-CoV-2 patients hospitalised in April—June 2020 was conducted under the inclusion criteria: age over 50 years, chest computed tomography (CT) for COVID-19-asso-ciated pneumonia, C-reactive protein (CRP) >50 mg/L, anticoagulant therapy, no contraindications to steroids, no biologic therapy. Cohort 1 patients (n = 96) received dexamethasone 4–12 mg/day, cohort 2 (n = 62) — a standard non-dexamethasone therapy.Results. Dexamethasone treatment associated with a significant alleviation of COVID-19-associated pneumonia in CT score (p = 0.001), reduced fibrinogen (p = 0.001), a trend to CRP reduction by day 8–10 and lower demand for oxygen therapy, including ventilatory support (p = 0.001). Mortality rate was 19.8 and 75.8 % in cohorts 1 and 2, respectively (p = 0.001).Conclusion. Dexamethasone therapy 4–12 mg/day in SARS-CoV-2 patients aged 50+ years with grade 3–4 CT changes receiving LMWH from start of hospitalisation significantly improved CT scores and reduced mortality.https://www.gastro-j.ru/jour/article/view/600covid-19dexamethasonecomputed tomographypneumonia conflict of interest: the authors declare no conflict of interest |
| spellingShingle | O. Yu. Zolnikova R. V. Maslennikov V. T. Ivashkin N. L. Dzhakhaya O. Yu. Kiseleva N. D. Potskhverashvili S. A. Shorokhova Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % Российский журнал гастроэнтерологии, гепатологии, колопроктологии covid-19 dexamethasone computed tomography pneumonia conflict of interest: the authors declare no conflict of interest |
| title | Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % |
| title_full | Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % |
| title_fullStr | Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % |
| title_full_unstemmed | Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % |
| title_short | Dexamethasone in Treatment of Comorbid SARS-CoV-2 Patients Aged over 50 Years with Lung Injury over 50 % |
| title_sort | dexamethasone in treatment of comorbid sars cov 2 patients aged over 50 years with lung injury over 50 |
| topic | covid-19 dexamethasone computed tomography pneumonia conflict of interest: the authors declare no conflict of interest |
| url | https://www.gastro-j.ru/jour/article/view/600 |
| work_keys_str_mv | AT oyuzolnikova dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 AT rvmaslennikov dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 AT vtivashkin dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 AT nldzhakhaya dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 AT oyukiseleva dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 AT ndpotskhverashvili dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 AT sashorokhova dexamethasoneintreatmentofcomorbidsarscov2patientsagedover50yearswithlunginjuryover50 |